This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmology, and organ preservation. It highlights the rise of generative biology, featuring multimodal protein foundation models that jointly reason over sequence, structure, and function to design novel proteins, AI platforms for de novo protein and cyclic peptide design, and machine learning systems that engineer CRISPR gene-editing tools for therapeutic development. The edition showcases clinical genomics platforms that automate variant interpretation and reporting, long-read sequencing approaches that resolve epigenetic modifications, gene-expression-based molecular diagnostics for early cancer detection, and cerebrospinal fluid seed-amplification assays that detect pathological alpha-synuclein for earlier, biomarker-driven Parkinson's diagnosis. It further covers nucleic acid and targeted therapeutics, including antisense RNA candidates for chronic hepatitis B, first-in-class telomerase-inhibiting oligonucleotides for lower-risk myelodysplastic syndromes, antibody-conjugated lipid nanoparticles for tissue-specific RNA delivery, and universal platforms enabling intracellular delivery of macromolecular drugs. Additionally, the TOE features precision small-molecule therapies such as selective HDAC6 inhibitors for neuromuscular and neurodegenerative disease and BRAF-directed agents for pediatric glioma, alongside next-generation delivery and device innovations including an implantable, wirelessly powered oxygen-generating device for immunosuppression-free islet transplantation, water-free ophthalmic formulations for dry eye disease, and digital-health-enabled precision dosing for ADHD. The edition also highlights next-generation immunotherapy for non-muscle invasive bladder cancer and cryoprotection-based strategies to improve hepatocyte survival and organ preservation. Collectively, these innovations reflect the accelerating convergence of AI-driven protein and drug design, genomic and molecular diagnostics, nucleic acid and small-molecule therapeutics, and engineered drug delivery. Together, they outline the future landscape of programmable, computationally guided medicine, earlier and more precise diagnosis, and scalable intervention across global health and wellness markets.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.